We’re pleased to share a significant update regarding Koselugo (selumetinib), a drug used to manage inoperable plexiform neurofibromas in NF1 patients. Recently, our pharmaceutical partner Alexion AstraZeneca Rare Disease informed us of a notable label change: patients no longer need to fast before taking Koselugo. This development marks a significant stride forward in patient convenience and treatment management.
For many families, adhering to a fasting schedule posed challenges, particularly when it involved waking up children to administer the medication. We understand the strain this can place on parents and patients alike. However, with this label change, those difficulties are now a thing of the past.
The latest data reveals that patients can now take Koselugo with or without food, with no discernible difference in its effectiveness. This newfound flexibility empowers patients to integrate their treatment regimen seamlessly into their daily lives, without the constraints of a fasting schedule. Post-market studies, such as this one to evaluate the need for fasting when taking Koselugo, are critical to expand the utility, indications and dosing for FDA-approved treatments.
For more information, please speak to your medical care professional, and/or contact an Alexion Patient Education Manager: https://koselugo.com/savingsandsupport#pem-finder
As advocates for the NF community, we understand the significance of sharing information that may impact patient care. It’s important to note that while we provide updates like this one, it’s not an endorsement of any specific treatment. Our aim is to offer valuable insights and advancements as a service to the community, empowering individuals to make informed decisions about their health. We celebrate milestones like this with you, acknowledging the collective effort to improve NF treatment options, while remaining committed to facilitating discussions and advancements in the field.
To learn more about CTF’s role in the development of MEK inhibitors as an NF treatment option, please visit: https://www.ctf.org/industry-partnerships/
